• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Phibro Animal Health (PAHC) Below Fair Value On Its Morgan Stanley Conference Appearance?

    Simply Wall St·09/15/2026 16:30:59
    Listen to the news

    Conference appearance puts Phibro Animal Health in focus

    Phibro Animal Health (PAHC) is set to present at Morgan Stanley's 24th Annual Global Healthcare Conference on September 15, 2026, drawing fresh investor attention to the animal health specialist.

    The session in New York features chief executive Daniel M. Bendheim, chief financial officer Glenn C. David and chief operating officer Larry L. Miller. It will give investors a concentrated look at how leadership frames growth priorities, capital allocation and market positioning.

    Phibro Animal Health enters the conference with a mixed tape, with the share price up 12.77% over 90 days yet down 3.65% year to date. Long-term total shareholder returns of 205.36% over three years suggest earlier momentum, while more recent 1-year weakness of 7.95% indicates that performance has cooled.

    See how Phibro Animal Health compares with other potential breakout opportunities by reviewing our curated list of 35 high quality undervalued stocks that share solid fundamentals and price support.

    Recent gains in Phibro Animal Health sit alongside weaker 1-year returns and stronger multi year performance. Is this latest move catching up with fundamentals, or just another swing in sentiment that the current valuation needs to answer?

    Most Popular Narrative: 21% Undervalued

    Analysts following Phibro Animal Health see fair value above the latest $35.94 close, with their models pointing to $45.60 using a 7.11% discount rate. That gap frames the conference appearance as a test of whether the story behind the numbers still holds.

    The company's strong recent growth is heavily dependent on the integration of the acquired Zoetis Medicated Feed Additive business and related cost synergies, which are non-repeatable. Forward guidance suggests legacy product growth will slow to flat or low single digits. This implies the current trajectory of accelerating revenue and EBITDA growth is unsustainable and likely to normalize, impacting revenue and earnings growth expectations.

    See why 9 investors see Phibro Animal Health as 21% undervalued.

    Result: Fair Value of $45.60 (UNDERVALUED)

    Still, two pressure points could upset the current Phibro Animal Health story: tougher regulation on medicated feed additives and any loss of momentum in higher margin vaccines and specialties.

    Find out about the key risks to this Phibro Animal Health narrative.

    Next Steps

    Mixed signals around Phibro Animal Health can be confusing, so act quickly, review the numbers yourself, and then weigh both sides of the story by reviewing 3 key rewards and 1 important warning sign

    Looking for more investment ideas beyond Phibro Animal Health?

    If Phibro Animal Health has your attention today, do not stop there. Use the Simply Wall St screener to hunt for other stocks that fit your checklist.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.